Novo Nordisk

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 54,400 people in 80 countries and markets its products in around 170 countries. For more information visit novonordisk.com.

Our US Research & Development hub, located in the Greater Boston area, brings together the best talent to drive life science innovation. Located in Lexington, Watertown and Cambridge, our teams reflect the full scope of R&D, from early research through late-stage clinical development. We are building for the future by creating a distinct R&D community based on collaboration, partnerships, and cutting-edge research across multiple modalities and therapeutic areas. We recognize that improving human health starts here and that patients rely on us. By combining the speed and agility of biotech with the quality, resources, and stability of a large pharmaceutical company, our US R&D hub will benefit from the best of both worlds to develop new medicines that meet the needs of patients.

Across Novo Nordisk, our people wake up every day knowing their work matters.
From the researcher analysing data, to the manufacturing specialist ensuring quality in every single dose, to the sales professional making sure our treatments reach the people who need them – our people share something powerful: the collective belief that science and innovation can truly transform lives.
It’s not always easy. Breakthroughs take years. Setbacks happen. But knowing that your work could bring hope to millions living with serious chronic diseases. That’s what keeps us going - driving lasting change for long-term health.

75 Hayden Avenue
Lexington, MA 02421

Tel: 617-612-6200

Visit website

NEWS

Yellow pills on blue background. Schedule Increase the dosage of drugs

Weight Loss

Despite Novo’s Robust Oral Wegovy Launch, Access Remains a Challenge for Obesity Drugs

This year’s catalysts in the space include a near-term FDA decision on Eli Lilly’s oral challenger to the new Wegovy pill. Looking further ahead, Novo Nordisk is expecting more clinical data for next-gen weight loss asset CagriSema, which recently lost a head-to-head battle with Lilly’s Zepbound.

March 25, 2026

3 min read

Heather McKenzie

Job Trends

11 Companies Hiring Now in New York

Looking for a biopharma job in New York? Check out the BioSpace list of 11 companies hiring life sciences professionals like you.

March 25, 2026

2 min read

Angela Gabriel

Traffic light in green color, with the dusk sky in the background.

Approvals

Novo’s High Dose Wegovy Scores FDA Priority Voucher Program’s 4th Nod

With the approval of Wegovy HD, Novo Nordisk joins Johnson & Johnson, Boehringer Ingelheim and USAntibiotics as beneficiaries of the FDA’s Commissioner’s National Priority Voucher program, which aims to review products that align with certain national priorities in less than two months.

March 19, 2026

2 min read

Heather McKenzie

Podcast

Kennedy’s Vaccine Agenda Stalled, Structure’s ‘Competitive’ Obesity Pill, Novo’s Warning Letter

Heath Secretary Robert F. Kennedy Jr.’s efforts to overhaul vaccine policy are likely illegal, a Massachusetts District Court Judge ruled; Structure’s GLP-1 weight loss pill succeeds in Phase 2 while Rhythm’s Phase 3 basket trial fails to find the beat; Eli Lilly warns of potential safety risks of taking compounded tirzepatide, and Novo Nordisk is hit with an FDA warning letter regarding adverse events potentially linked to Ozempic.

March 18, 2026

1 min read

Heather McKenzie

Jamaica economic collapse, decreasing values with coins, crisis and downgrade concept, Jamaica flag with changes, falling arrow, news banner idea, fail and decrease, financial decline

Earnings

Novo Holdings’ Assets Fell 34% in 2025 As Its Namesake Drugmaker Struggled

Total assets under management for Novo Holdings, Novo Nordisk’s controlling shareholder, fell by more than one-third last year. The report caps off a tumultuous year for the Novo group of companies.

March 12, 2026

1 min read

Annalee Armstrong

Illustration of a yellow envelope on a blue background with a read warning symbol

GLP-1

Novo Hit With FDA Warning Letter for Unreported Ozempic Safety Signals

Among the unreported adverse events potentially linked to Ozempic are two deaths and one case of “completed suicide,” according to an FDA inspection report.

March 11, 2026

2 min read

Tristan Manalac

Podcast

Prasad Out at FDA, Lawmaker Takes Action on Rare Disease Rejections, and a Spate of Obesity Data

Rare disease biotech stocks pop on the news that Vinay Prasad, the FDA’s chief biologics regulator, will depart the FDA at the end of April; Sen. Ron Johnson launches an investigation into recent rare disease drug rejections; and Roche and Zealand’s amylin analog fails to match investor expectations—and Eli Lilly’s rival candidate—in a mid-stage trial.

March 11, 2026

1 min read

Heather McKenzie

Podcast

UniQure’s Delay, REGENXBIO’s Rejection Explained, Sarepta’s Ingram Steps Down, More

UniQure and REGENXBIO are both dealing with FDA setbacks for their respective gene therapies, as regulatory experts question the FDA’s decision-making processes; CBER director Vinay Prasad is under probe for allegedly fostering a toxic workplace; Sarepta CEO Doug Ingram is stepping down after several years of tumult at the top of the muscular dystrophy–focused company; and Eli Lilly again tops Novo Nordisk in a weight loss trial.

March 4, 2026

1 min read

Heather McKenzie